This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma

This study has been completed.
UCB Pharma
Information provided by (Responsible Party):
Pfizer Identifier:
First received: March 24, 2009
Last updated: July 17, 2013
Last verified: July 2013
The purpose of this study is to evaluate the efficacy of inotuzumab ozogamicin (CMC-544) in subjects with indolent Non-Hodgkins lymphoma (NHL) that is refractory or has relapsed after multiple therapies including rituximab or radioimmunotherapy. The investigational drug will be given to subjects with indolent NHL by intravenous infusion at a dose of 1.8 mg/m2, every 4 weeks.

Condition Intervention Phase
Lymphoma Drug: Inotuzumab Ozogamicin (CMC-544) Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Study Of Inotuzumab Ozogamicin (CMC-544) In Subjects With Indolent Non-Hodgkin's Lymphoma (NHL) That Is Refractory To Or Has Relapsed After Rituximab And Chemotherapy Or Radioimmunotherapy

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Response rate of subjects with indolent NHL treated with inotuzumab ozogamicin as measured by CT/MRI scans at regular intervals. [ Time Frame: 12 months ]

Secondary Outcome Measures:
  • Safety and tolerability of inotuzumab ozogamicin in the treatment of subjects with indolent NHL. [ Time Frame: 24 months ]
  • Further assess the response rate of subjects with indolent NHL treated with inotuzumab ozogamicin by evaluating the complete response (CR) rate, duration of response (DR), progression free survival (PFS) and overall survival (OS). [ Time Frame: 24 months ]
  • Determine the ORR, CR, DR, PFS and OS in subjects with follicular NHL treated with inotuzumab ozogamicin. [ Time Frame: 24 months ]
  • Evaluate the population pharmacokinetic (PK) profile of inotuzumab ozogamicin. [ Time Frame: 24 months ]
  • Evaluate the concentration-effect relationship of cardiac QT measures. [ Time Frame: 24 months ]

Enrollment: 81
Study Start Date: July 2009
Study Completion Date: June 2013
Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: inotuzumab ozogamicin
inotuzumab ozogamicin
Drug: Inotuzumab Ozogamicin (CMC-544)
Administered intravenously at 1.8 mg/m2 every 4 weeks for a planned 4 - 8 cycles
Other Name: inotuzumab ozogamicin


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects who have been previously diagnosed with CD22-positive, indolent NHL (defined as follicular, marginal zone, or small lymphocytic lymphoma) that has progressed after 2 or more prior systemic therapies.
  • Previous anticancer treatment given must have contained rituximab and chemotherapy, or anti CD20 Radio Immuno Therapy. Subjects must have exhibited no response or have progressed within 6 months from the completion of the most recent rituximab or rituximab containing therapy or within 12 months of the completion of Radio Immuno Therapy.
  • Measurable disease with adequate bone marrow function, renal and hepatic function

Exclusion Criteria:

  • History of, or suggestive of, veno-occlusive disease (VOD) or sinusoidal obstruction syndrome (SOS) or history of chronic liver disease (eg, cirrhosis) or suspected alcohol abuse.
  • Prior allogeneic hematopoietic stem cell transplant (HSCT).
  • Clinical evidence of transformation to a more aggressive subtype of lymphoma or grade 3b follicular lymphoma.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00868608

  Show 29 Study Locations
Sponsors and Collaborators
UCB Pharma
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Pfizer Identifier: NCT00868608     History of Changes
Other Study ID Numbers: 3129K7-2001
Study First Received: March 24, 2009
Last Updated: July 17, 2013

Keywords provided by Pfizer:
Refractory Indolent NHL

Additional relevant MeSH terms:
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases processed this record on August 23, 2017